Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632653 | 0.86 | HCRTR2 (0.49) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL1631243 | 0.86 | KDM4E (0.44) | ALDH1A1KDM4EHPGD | |
| SCHEMBL1632058 | 0.85 | HTR4 (0.43) | ALDH1A1TYRO3KDM4EHPGDNAMPT | |
| SCHEMBL1630900 | 0.84 | HTR2A (0.42) | ALDH1A1TYRO3KDM4EHPGDNAMPT | |
| SCHEMBL1629943 | 0.84 | HTR2A (0.42) | ALDH1A1TYRO3KDM4EHPGDNAMPT | |
| SCHEMBL1632978 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TYRO3KDM4EHPGDNAMPT | |
| SCHEMBL1630654 | 0.80 | HCRTR2 (0.45) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL1629532 | 0.80 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGD | |
| SCHEMBL1630302 | 0.80 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGD | |
| SCHEMBL12724230 | 0.80 | CHRM1 (0.45) | ALDH1A1KDM4EHPGDNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | HCRTR1 3678/4885HCRTR2 3234/4885ALDH1A1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.